Open Access

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study

  • Authors:
    • Anjie Zhu
    • Peng Yuan
    • Jiayu Wang
    • Ying Fan
    • Yang Luo
    • Ruigang Cai
    • Pin Zhang
    • Qing Li
    • Fei Ma
    • Binghe Xu
  • View Affiliations

  • Published online on: April 2, 2019     https://doi.org/10.3892/ol.2019.10205
  • Pages: 4768-4778
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Locally advanced or metastatic disease accounts for the majority of breast cancer‑associated cases of mortality. Treatment options for patients with locally advanced or metastatic disease are limited. The current study aimed to explore the efficacy and safety of apatinib combined with chemotherapy in patients with previously treated advanced breast cancer in real‑world clinical practice. A total of 85 patients with advanced breast cancer, who had previously been exposed to anthracyclines or taxanes, received combined treatment. Tumor response was evaluated by a computed tomography scan based on the Response Evaluation Criteria in Solid Tumors. Adverse events were graded based on the Common Terminology Criteria for Adverse Events. The Kaplan‑Meier method and a log‑rank test were used to analyze the univariate discrimination of progression‑free survival (PFS) and overall survival (OS) by demographic data, baseline clinical information and toxicities. The combined effects of these variables were analyzed by a Cox proportional hazards regression model. At a median follow‑up time of 9.7 months, 73 patients exhibited disease progression and 48 had succumbed to the disease. During the follow‑up, 19 patients demonstrated a partial response (PR) and 53 patients achieved stable disease (SD), with an objective response rate of 23.2%. Additionally, 39 patients demonstrated a PR or SD for ≥24 weeks, with a clinical benefit rate of 47.6%. The median PFS was 4.4 months [95% confidence interval (CI)=2.8‑6.0] and the median OS was 11.3 months (95% CI=8.9‑13.8). No treatment‑associated mortalities occurred. The most common adverse events of all grades included myelosuppression (49.4%), gastrointestinal reaction (45.9%) and fatigue (43.5%). Proteinuria was an independent predictive factor for PFS and OS. Apatinib combined with chemotherapy appeared to be efficacious for pretreated advanced breast cancer, with acceptable toxicity for real‑world clinical practice.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Mayer EL and Burstein HJ: Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 21:257–272. 2007. View Article : Google Scholar : PubMed/NCBI

4 

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al: Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 16:310–320. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Schneider BP and Miller KD: Angiogenesis of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Fox SB, Generali DG and Harris AL: Breast tumour angiogenesis. Breast Cancer Res. 9:2162007. View Article : Google Scholar : PubMed/NCBI

7 

Banerjee S, Dowsett M, Ashworth A and Martin LA: Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 4:536–550. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:145–147. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L and Gianni L: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 20:616–624. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR and Perez EA: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North central cancer treatment group and mayo clinic trial N0336. J Clin Oncol. 27:11–15. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 26:1810–1816. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Yardley DA, Dees EC, Myers SD, Li S, Healey P, Wang Z, Brickman MJ, Paolini J, Kern KA and Citrin DL: Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat. 136:759–767. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P and Paridaens R: Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 123:463–469. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 121:121–131. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Mariani G, Burdaeva O, Roman L, Staroslawska E, Udovitsa D, Driol P, Goisis G, Zamagni C, Semiglazov V and Gianni L: A double-blind, randomized phase lib study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01 Trial. Eur J Cancer. 47:102011. View Article : Google Scholar

17 

Hudis C, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani VG, Stepanski EJ, Rugo HS, Wang W, et al: Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol. 29:1009. 2011. View Article : Google Scholar

18 

Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA and Schwartzberg L: A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 49:312–322. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, et al: Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 30:1484–1491. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Aalders KC, Tryfonidis K, Senkus E and Cardoso F: Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treat Rev. 53:98–110. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI

22 

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI

24 

U.S.Department of Health, Human Services, National Institutes of Health and National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. simplehttps://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdJune 14–2010

25 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al: The transcriptional landscape of the mammalian genome. Science. 309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI

27 

Gerard T: Eastern Cooperative Oncology Group Performance Status. Chemotherapy. 5:102012.

28 

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Xu J, Liu X, Yang S, Zhang X and Shi Y: Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: A retrospective study. Onco Targets Ther. 10:4989–4995. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Lin Y, Wang C, Gao W, Cui R and Liang J: Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget. 8:42252–42261. 2017.PubMed/NCBI

31 

Liu L, Yu H, Huang L, Shao F, Bai J, Lou D and Chen F: Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther. 8:921–928. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Huang L, Wei Y, Shen S, Shi Q, Bai J, Li J, Qin S, Yu H and Chen F: Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. Oncotarget. 8:29346–29354. 2017.PubMed/NCBI

33 

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet. 377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:485–493. 1999. View Article : Google Scholar : PubMed/NCBI

35 

Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B and Schmid P: Biweekly pegylated liposomal doxorubicin (caelyx) in heavily pretreated metastatic breast cancer: A phase 2 study. Clin Breast Cancer. 16:514–519. 2016. View Article : Google Scholar : PubMed/NCBI

36 

Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK and Fu LW: Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 83:586–597. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI

38 

Zhu J, Li X, Xie C, Li Y and Zhong G: Apatinib, a new small molecular VEGFR2 inhibitor, suppresses the activity of lung cancer stem cells. J Thorac Oncol. 12 (Suppl 1):S12792017. View Article : Google Scholar

39 

Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI

40 

Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, et al: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: A cohort study. J Hematol Oncol. 10:1532017. View Article : Google Scholar : PubMed/NCBI

41 

Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z and Hu X: Phosphorylated VEGFR2 and hypertension: Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 143:141–151. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhu, A., Yuan, P., Wang, J., Fan, Y., Luo, Y., Cai, R. ... Xu, B. (2019). Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. Oncology Letters, 17, 4768-4778. https://doi.org/10.3892/ol.2019.10205
MLA
Zhu, A., Yuan, P., Wang, J., Fan, Y., Luo, Y., Cai, R., Zhang, P., Li, Q., Ma, F., Xu, B."Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study". Oncology Letters 17.6 (2019): 4768-4778.
Chicago
Zhu, A., Yuan, P., Wang, J., Fan, Y., Luo, Y., Cai, R., Zhang, P., Li, Q., Ma, F., Xu, B."Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study". Oncology Letters 17, no. 6 (2019): 4768-4778. https://doi.org/10.3892/ol.2019.10205